Global Shigella Infections Market - 2023-2030

Overview

Shigellosis is a foodborne sickness that can be brought on by a genus of bacteria called Shigella. Shigellosis is characterized by symptoms like vomiting, fever, diarrhea (sometimes bloody), and abdominal pain. The infection is typically spread by the fecal-oral route, which is frequently brought on by poor hygiene habits, tainted water or food, and crowded living situations.

With an emphasis on diagnosis, treatment, and prevention, the healthcare and pharmaceutical industries dominate the market for Shigella infections. Pharmaceutical businesses that make medications to treat Shigella infections, diagnostic tool providers, and public health activities to stop the disease's spread are all included in this sector.

Dynamics

Increasing Prevalence of Shigella Infections

As per the article published by the International Journal of Molecular Sciences in 2023, shigellosis is a common infectious disease spread by several Shigella species through the intake of tainted food and water, and it is a challenge for both rich and developing nations' public health. But due to person-to-person transmission, the incidence of shigellosis is also notably high in homosexual males. Epithelial cells from the colon, ileum, and rectum invade, which is what causes it. Shigella infections can affect persons of any age, but sensitive populations have seen more cases than others.

Worldwide, diarrheal illnesses are responsible for more than a million fatalities each year. However, shigellosis is thought to be responsible for over 164,000 annual deaths, particularly in young children. Shigella species are also thought to be responsible for about 125 million cases of diarrhea each year. Shigellosis affects people all around the world and causes serious economic losses in addition to public health issues.

Vaccine Development

Shigella bacteria are the source of the intestinal infection known as shigellosis. Diarrhea, fever, abdominal pain, and the need to pass feces even when the bowels are empty are among the symptoms that typically appear one to two days after contact. The majority of Shigella strains develop antibiotic resistance. The World Health Organization (WHO) has deemed developing an effective Shigella vaccine candidate to be a public health priority due to the lack of an authorized vaccine.

By enhancing the specificity and potency of vaccines using nanotechnology, it plays a special role in their development. Antigens easily absorb nanoparticles smaller than 500 nanometers, making them suitable carriers for the delivery of adjuvants and vaccination antigens. Antigens/adjuvants are either enclosed within or embellished on the surface of nanoparticles for their benefits, which include increased antigen stability, targeted administration, and long-term release.

Increasing Need to Develop New Antibiotic

Because human use so many antibiotics in both veterinary medicine and their health care, they are generally observing an increase in drug resistance in pathogenic bacteria. Current therapies seldom completely eradicate all bacteria, some survive and propagate their resistance genes, overusing antibiotics results in the development of resistance mechanisms.

Furthermore, bacteria that have developed the genetic resources to withstand antibiotics can trade these resources with one another, even with bacteria from closely related species. These highly drug-resistant Shigella strains are alarming because of this. To stop this there is a need to develop new antibiotics solutions to treat these types of infections.

Awareness and Education

To prevent and treat Shigella infections, awareness and education are essential. People and communities can better grasp the dangers, modes of transmission, and preventative actions connected with shigellosis with the use of effective communication and education efforts. The significance of good hand hygiene, safe food handling, and clean water sources can be emphasized in awareness campaigns. Shigella germs can be prevented from spreading by instructing individuals on proper hand-washing techniques and food safety procedures.

For instance, in 2022, One meeting was held in Asia, where topics included new initiatives and difficulties, enteric bacterial illnesses like Shigella spp., epidemiology, burden, and vaccinations against other viral infections including hepatitis, as well as the lessons learned from research on diarrhea during the COVID pandemic.

Antibiotic Resistance

In the context of Shigella infections as well as the larger field of infectious illnesses, antibiotic resistance is a major concern. When bacteria, like Shigella, acquire the ability to survive and proliferate in spite of exposure to antibiotics that were once successful in treating infections, this phenomenon is known as antibiotic resistance. Common antibiotics may no longer be effective due to this resistance, making infections harder to treat and raising the risk of life-threatening sickness, complications, and even death.

Antibiotic misuse, such as taking them without a prescription or skipping a recommended course, might hasten the emergence of resistance. Shigella infections have historically received excessive antibiotic treatment, which has put pressure on the bacteria to evolve resistance.

Vaccine Development Challenges

The nature of the bacteria and the sickness they cause make developing a vaccine for Shigella infections difficult. Although there has been progress, these difficulties have increased the difficulty of developing efficient vaccinations. On the basis of their surface antigens, Shigella bacteria are classified into various serotypes. It is difficult to develop a vaccine that offers comprehensive protection against all serotypes because immunization to one serotype may not offer cross-protection against another.

It has proved challenging to develop long-lasting immunity following natural infection or immunization. Some vaccinations have demonstrated a limited shelf life in terms of promoting protective immunity, necessitating replenishment shots to be effective.

Segment Analysis

The global shigella infections market is segmented based on drug class, type, route of administration, distribution channel, and region.

Increasing Prevalence of Shigella Sonnei Infection

Men who have intercourse with other men (MSM) are sexually susceptible to shigellosis, which is a serious digestive disease. Shigella sonnei is the source of this condition. Azithromycin and ciprofloxacin, two medications that the World Health Organization recommends as first-line therapies, are frequently resistant to several drugs in S. sonnei. Antibiotic-resistant Shigella sonnei is the primary cause of bacillary dysentery in high-income nations.

For instance, in response to an extraordinary rise in cases of Shigella sonnei infection and travel history to Cabo Verde, the Netherlands opened an event in EpiPulse, a restricted communications platform run by ECDC, in November 2022. Travelers returning from Cabo Verde had been infected with Shigella sonnei in numerous EU/EEA countries, the UK, and the US by the end of 2022. In addition, each year, the UK Health Security Agency (UKHSA) receives notifications of about 1650 cases of shigellosis, with S. sonnei being the most often found species.

Geographical Penetration

Advanced Healthcare Infrastructure and Active Major Players

North America has been a dominant force in the global shigella infections market. Shigellosis cases that have been recorded through national surveillance systems have increased, according to the Centers for Disease Control and Prevention (CDC). XDR strains were responsible for 5% of Shigella infections reported to the CDC in 2022 as opposed to 0% in 2015.

Limited antibiotic therapy options are available to clinicians caring for individuals infected with XDR strains. The germs Shigella are very contagious. Antibiotic resistance genes can be transferred from XDR Shigella strains to other intestinal bacteria. Aware of these potentially serious public health issues, the Centers for Disease Control and Prevention (CDC) urges medical professionals to be watchful in spotting and reporting suspected XDR Shigella infection cases to their regional or state health departments as well as informing patients and communities at higher risk about prevention and transmission.

In the United States, shigellosis, an acute enteric infection, is a significant contributor to both domestically acquired and travel-related bacterial diarrhea. Azithromycin, ciprofloxacin, or ceftriaxone are suggested empiric antimicrobial medications in the United States. For strains that are vulnerable, other therapies like ampicillin or TMP-SMX are advised.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global shigella infections market. Spending for research, therapies, and preventive plans for other infectious diseases including Shigella infections may have been affected by the pandemic's priority for global health spending.

People's ability to seek medical assistance for a variety of illnesses, including Shigella, may have been impacted by the pandemic's effects on healthcare access, particularly in low-resource areas. The COVID-19 pandemic's emphasis on cleanliness and handwashing may have indirectly helped avoid Shigella infections by encouraging communities to adopt better hygiene.

Russia-Ukraine War Impact Analysis

Basic services including the provision of clean water, sanitary conditions, and garbage disposal can be disrupted by conflicts. Shigellosis and other waterborne illnesses are more likely to spread when there is insufficient access to clean water and sanitary facilities. Due to the emphasis on wounds and stress associated with conflict, healthcare services may be disrupted.

During these periods, routine healthcare services, such as disease surveillance, can be neglected, which could result in underreporting and a delay in responding to infectious disease outbreaks. Conflict-related population displacement can result in overcrowded and unhealthy circumstances in refugee camps or other makeshift communities. These circumstances foster an atmosphere that is favorable for the spread of infectious diseases, such as infections caused by shigella caused by polluted water and poor hygiene.

By Type

• Dysenteriae
• Flexneri
• Boydii
• Sonnei

By Drug Class

• Ciprofloxacin
• Azithromycin
• Others

By Route of Administration

• Injectable
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2023, the University of Maryland School of Medicine (UMSOM) in Baltimore and the Chief of Adult Clinical Studies at UMSOM's Center for Vaccine Development and Global Health (CVD) both announced the successful, full enrollment of Intralytix, Inc.'s Phase 1 clinical trial. ShigActive, a phage therapy product from Intralytix intended to prevent or lessen the severity of Shigella infections, is the subject of a clinical investigation to evaluate its safety. The National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, is contributing money to the trial.

Competitive Landscape

The major global players in the market include: Emergent BioSolutions, Inc., Pfizer, Inc., Aurobindo Pharma, LimmaTech Biologics AG, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Mylan N.V., Lupin Limited, Sun Pharmaceutical Industries Ltd., and Zydus Cadila.

Why Purchase the Report?

• To visualize the global shigella infections market segmentation based on drug class, type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Shigella Infections market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global shigella infections market report would provide approximately 77 tables, 79 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies